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Insulin resistance and adverse metabolic profile in 
overweight/obese and normal weight of young women  
with polycystic ovary syndrome 
 
Abstract 
Background: Polycystic ovary syndrome (PCOs) is an endocrine-metabolic disorder. This 
study intends to determine the comparison of insulin resistance (IR) and metabolic 
disturbance in overweight/obese and normal-weight of young women with polycystic 
ovary syndrome. 
Methods: Using a comparative cross-sectional study design in 2015, 27 normal weight 
(18<BMI<25) and 85 overweight/obese (BMI≥25) aged 18 and 35 underwent clinical 
measures of HOMA  (IR) as  insulin resistance and QUICKI as insulin sensitivity tools in 
Fatemezahra Infertility Research Center of Babol. Lipid profile and hormonal parameters 
were evaluated between two groups. 
Results: 112 women with PCOS participated in this study. The mean age was 22.4±3.48 
years in the normal PCOS group (n=27) and 24.4±5.06 years in the overweight/obese 
PCOS patients (n=85). BMI had a significant straight correlation with insulin resistance 
(p<0.001) and a negative correlation with insulin sensitivity (p<0.001). BMI showed a 
straight stronger correlation with triglyceride (TG) (p<0.001) and LDL cholesterol (<0.05) 
and a stronger reverse relationship with SHBG (p<0.001). In overweight/obese group, 
91.7% (48) of the women showed insulin resistance (HOMA>3.15) vs. 8.3% (5) in the 
normal group (P<0.001). 82.4% (62) of the overweight/obese group revealed low insulin 
sensitivity (QUICKI<0.34) while this value was 17.6 % (13) within their lean counterparts 
(p<0.001). In the study group, 89.7 % (54) showed elevated fasting insulin concentration 
(>13µU/ml) vs. 10.3% (7) in the control group (p<0.001). 
Conclusions: Overweight/obese PCOs patients revealed higher insulin resistance and 
lower insulin sensitivity, and also greater TG and LDL cholesterol. Priority of 
management of insulin resistance and lipid profile should be considered on identifying 
these potentially major complications. 
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Insulin resistance (IR) is a growing public health concern worldwide. Co-occurrence 
of IR, as a well-established contributor of metabolic syndrome is regarded in women with 
PCOs (1). Glucose intolerance in PCOS women occur at an earlier age than in the normal 
ovary women (in the 3rd-4th decades of life) (2). The PCOs women may involve several 
fold more likely to have increased risk of aggravating type II diabetes and an excess risk of 
impaired glucose tolerance, and more suffering from diabetes at young age (3-8). 
Approximately, half of the women with PCOs are overweight or obese. They involve 10-
year incidence of major weight gain (9). Obesity aggravates extended medical implications 
in women with PCOs. On the other hand, greater prevalence of metabolic abnormalities is 
seen in the presence of obesity alongside PCOs phenotype (10-12). 
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In a study, 57% of overweight/obese women with PCOs 
are insulin resistant, while the prevalence was 9.3 % in the 
lean counterparts. In addition, insulin sensitivity (IS) was 
reduced 50% in obese PCOs from that in lean controls (13). 
Even augmenting BMI by 1 kg/m
2
 reduces IS indexed 
further in PCOs patients versus in controls (14). Recent 
evidence has suggested that adiposity contributes as an 
additional component to IR in obese PCOs (15-18), however, 
not a defining criteria for PCOs (14). Hence, weight loss 
through lifestyle modification improves IR and reduces and 
detracts PCOS clinical manifestation intensity (19). 
Although, IR may be a multifactorial feature; particularly 
race and age have an important role as well as BMI (20). 
Higher fasting insulin and lower IS were seen in South 
Asians, African Americans and Hispanic women with PCOs 
at a younger age with severe manifestations than Caucasians 
(21-22). IR is an independent risk factor for clinical, 
metabolic, reproductive, and psychological problems of 
overweight/obese PCOs women (23) from diabetes mellitus, 
hypertension, cardiovascular disease to resistance to weight 
loss, ovulation disturbance, irregular menstruation, 
hyperandrogenism, infertility, increased miscarriage rate and 
even psychological distress (24), yet a considerable amount 
of respective literature has been published on IS regarding 
Caucasian women. Thus, little reliable evidence in the 
Middle East with its related races or the measurement tools 
for calculating IR was not attributable.  
In this study, we assess the comparison of insulin 
resistance and some biochemical features in lean and 
overweight/ obese young women with PCOs.  
 
 
Methods 
Participants: The Ethics Committee of Babol University of 
Medical Sciences approved the study protocol. This 
comparative cross-sectional study was conducted on a total 
of 112 PCOs (27 women with normal weight and 85 
overweight obese women) aged 18 to 35, who referred to  
the PCOs clinic of Infertility Research Center in Babol 
(Iran), from April to September 2015.  
The sample size was calculated according to previous related 
papers. We recruited the samples amongst the women with 
PCOs admitted in the clinic. All participants were or their 
first visit prior to the initiation of any infertility co-treatment 
or main treatment. PCOs was defined according to the 2003 
Rotterdam consensus criterion (25). Diagnosis of PCOs was 
based on ultrasound, clinical and biochemical criteria. 
Ultrasound criteria were used to detect polycystic ovaries, 
defined as the presence of at least 12 follicles of 2 to 9-mm 
diameter, and/or increased ovarian volume (> 10 ml). 
Clinical criteria included amenorrhea or oligomenorrhea (a 
cycle length >35 days or six menstrual periods per year). 
Moreover, patients who were diagnosed as PCOs had 
hirsutism assessed using Ferriman and Gallway score system 
(≥ 8), acne and alopecia. Biochemical criteria included 
elevated menstrual LH/FSH ratio (>2) or elevated serum 
testosterone (>2.8) nmol/L and or biochemical signs of 
hyperandrogenism including: increased circulating level of 
total or free testosterone, or dehydroepiandrosterone sulfate 
(DHEAS), while the other causes of hyperandrogenism had 
been excluded.  
The patients with the following conditions were also 
excluded from this study: pregnancy, hyperprolactinemia, 
thyroid dysfunction, hypertension, gastrectomy, cigarette 
smoking, chronic alcohol consumption, contraceptive pills 
and anti-obesity, strenuous physical activity and the women 
who were not exposed to any infertility treatments. The 
selected PCOs patients were divided into two groups based 
on BMI; 18-25 normal weight, ≥25 overweight and obese. 
BMI was calculated using the formula: [weight/height
2
;
 
(kg/m
2
)]. Waist circumference to hip circumference ratio 
was calculated in all patients. The patients were matched on 
the basis of age. 
Laboratory assays: We preferred to choose HOMA (IR) 
(homeostatic assessment of IR tool) and fasting insulin in the 
assessment of IR and QUICKI (quantitative IS check index 
to investigate IS for their simplicity and identical diagnostic 
accuracy in our participants at risk of diabetes (26-28). 
HOMA-IR and QUICKI were calculated according to the 
following formula: HOMA-IR= [fasting insulin (µIU/ml) × 
fasting glucose (mg/dl)]/405 and QUICKI = [(1/(log fasting 
insulin (µIU/ml) + log fasting glucose (mg/dl)] indexes (29). 
IR specific for PCOs women was defined as HOMA-IR 
greater than 3.15 (13), abnormal fasting insulin (<7 and >13 
mIU/l) and fasting plasma glucose >100.9 µg/dl (5.7 mmol/L 
or 5.6 mmol/L or more) (30). All hormonal and biochemical 
experiments were performed in a private pathobiology 
laboratory in Babol, Iran. Blood samples (~ 10 mL) were 
collected from each patient after an overnight fast for at least 
12 hr. The samples were immediately cooled, serum and 
plasma were separated within 1 h and stored at -20° C until 
assayed. Biochemistry analysis including FBS; fasting blood 
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sugar (mg/dl), fasting insulin (µg/dl) cholesterol (mg/dl), 
triglycerides (mg/dl), HDL-C; high-density lipoprotein-
cholesterol (mg/dl), LDL-C; low-density lipoprotein- 
cholesterol (mg/dl) were measured with Azmoon kit ( Pars 
Azmoon kit, Pars Azmoon Inc., Tehran, Iran) by the 
spectrophotometry method (Hitachi 911 Chemistry analyzer, 
Germany). We used optimal cutoff TG≥68.5 for normal 
weight and ≥100.5 mg/dl for overweight/ obese women as a 
marker for predicting IR according to Park (31). Serum 
insulin (µU/ml) was analyzed via IRMA: 
immunoradiometric assay kit (BI-insulin IRMA; Bio-Rad, 
Marnes la Coquette, France).  
Hormonal analysis including serum 17-OH-progestrone 
level (ng/ml) was measured using a radioimmunoassay 
(RIA ). Serum levels of prolactin (mlu/L), testosterone 
(ng/ml), DHEAS; dehydroepiandrosterone sulphate (µg/dl), 
FSH; follicle-stimulating hormone (mIu/ml), LH; luteinizing 
hormone (mIu/ml) were performed with chemiluminescence 
immunoassay kit (CLIA). TSH; thyroid stimulating hormone 
(mIu/mL) was determined with IRMA: immunoradiometric 
assay. SHBG; sex hormone binding globulin (nmol/L) was 
measured by electrochemiluminescence assay kit (ECL). 
Free testosterone (pg/mL) was analyzed using ELISA Kit. 
Statistical analysis: Statistical tests were performed using 
SPSS 16 for Windows software (SPSS Inc., Version 18, 
Chicago, IL, USA). The difference mean of all parameters 
between the study groups were done using t- test. Log 
transformation analysis of correlation between BMI and 
hormonal and biochemical tests was performed using 
Pearson’s bivariate correlation coefficient. The results were 
expressed as mean±S.D. For testing the differences in the 
frequencies of classified HOMA (IR), QUICKI, and fasting 
insulin in normal and overweight/obese PCOs women, chi-
square was used. For all analyses, a 2-tailed p-value of 0.05 
or less was considered statistically significant. Data were 
presented as means and standard deviations. 
 
 
Results  
112 women with PCOs participated in this study. The 
study group included 85 (75.9%) overweight /obese PCOs 
subfertile women with BMI ≥25 and control group 
27(26.5%) with normal weight PCOs with BMI<25. The 
anthropometric parameters of age, BMI, waist/hip ratio, 
hirsutism by Ferriman-Gallwey score of normal, overweight/ 
obese PCOS participants were summarized in table 1.  
Table 1. Anthropometric parameters in normal and 
overweight/obese PCOs women 
 
 Normal weight 
(n=27) 
Overweight-obese 
(n=85) 
 Mean±SD Mean±SD 
Age (years) 22.4±3.48 24.4±5.06 
BMI (kg/m
2)
 22.37±2.26 30.86±3.84 
Waist/hip ratio 0.76±0.09 0.86±0.94 
Hisrsutism
1 
12.11±6.36 12.85±5.49 
 Data was shown by descriptive test. 
1 Ferriman and Gallway score 
 
Mean age was 22.4±3.48 years in the normal PCOs group 
(n=27) and 24.4±5.06 years in the overweight/obese PCOs 
patients (n=85). Correlation between variables: Correlation 
analysis between BMI and biochemical, hormonal 
parameters of women with PCOs is presented in table 2. 
Table shows the variables which are in correlation with BMI. 
It is apparent that the strongest straight correlation is 
between BMI with fasting insulin r=0.55.  
Additionally, it is quite revealing that BMI had a 
significant positive correlation with HOMA (IR), r= 0.47, 
and also a significant reverse correlation with QUICKI, r=-
0.53 (table 2).  
 
Table 2. Correlation analysis between BMI and 
hormonal and biochemical parameters of women with PCOs 
 
P value* R  Dependent variable 
0.04 -0.12 LH (mIU/ml) 
<.001 -0.48 SHBG (nmol/L) 
<.001 0.39  Triglyceride (mg/dl) 
0.01 0.24  LDL-cholesterol (mg/dl) 
<.001 0.55  Fasting insulin (µU/dl) 
<.001 -0.53 QUICKI   
<.001 0.47  HOMA(IR)  
* The data were analyzed by logistic regression. 
HOMA-IR: Insulin resistance calculated using HOMA model  
QUICKI: Insulin sensitivity calculated using QUICKI model 
 
Metabolic assessment and hormonal profiling of two 
groups of PCOs patients divided based on BMI was 
illustrated in table 3. Overweight- obese PCOs women 
significantly achieved higher HOMA-IR and QUICKI 
(p<0.001), (p<0.001), respectively (table3). The difference in 
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lipid profile containing triglyceride and LDL cholesterol 
values were higher in the overweight/obese PCOs women 
reaching the level of statistical significance (p<0.05), 
(p<0.05), respectively. Also, HDL was lower in the 
overweight/obese women than the lean PCOs group (p≤0.05) 
(table 3).  
 
Table 3. Biochemical parameters in normal and overweight/obese PCOS women  
 
 Normal 
(n=27) 
Overweight-obese 
(n=85) 
P-value* 
 Mean±SD Mean±SD 
FSH (mIU/ml) 6.72 ± 2.03 6.52 ± 1.72 0.62 
LH (mIU/ml) 8.69 ± 3.96 8.3 ± 4.28 0.65 
LH/FSH ratio 1.29 ± 0.49 1.29 ± 0.8 0.99 
Free-testosterone (pg/ml) 2.85 ± 1.47 2.79 ± 1.06 0.78 
Testosterone (ng/ml) 1.08 ± 1.67 0.9 ± 1.13 0.54 
17-OH-progesterone (ng/ml) 1.31 ± 1.79 1.14 ± 0.91 0.587 
DHEAS (µg/dl)) 179.09 ± 86.36 172.7 ± 73.64 0.71 
SHBG (nmol/L) 45.24 ± 29.6 29.19 ± 13.31 0.01 
TSH (mIU/ml) 2.18 ± 1.24 2.3 ± 1.17 0.67 
Prolactin (mlU/L) 374.74± 185.8 265.11± 152.79 0.02 
Fasting insulin (µU/ml) 10.87 ± 6.99 16.78 ± 7.41 <0.001 
Fasting glucose (mg/dl) 87.87 ± 9.27 89.01 ± 11.04 0.6 
Triglyceride (mg/dl) 98.37 ± 27.46 139.4 ± 64.15 0.03 
Total cholesterol (mg/dl) 175.77 ± 39 184.08 ± 37.49 0.33 
LDL-cholesterol (mg/dl) 91.52 ± 8.92 104.52± 23.71 0.02 
HDL-cholesterol (mg/dl) 58.27 ± 8.78 53.71± 12.84 0.01 
QUICKI < 0.34  0.37±0.03 0.31±0.01 <0.001 
HOMA (IR) ≥ 3.15 2.01± 0.38 5.15 ± 1.93 <0.001 
  * t-Test.                                                 Overweight (body mass index [BMI] ≥25 kg/m2 
  HOMA-IR: Insulin resistance calculated using HOMA model          QUICKI: Insulin sensitivity calculated using QUICKI model 
 
After applying TG cutoff (≥68.5 for normal weight and 
≥100.5 mg/dl for overweight/ obese) that was defined by 
Park as a marker for predicting IR (HOMA-IR≥2.5) (31), the 
results revealed that 18.2% (2) women in the normal group 
had TG greater than 67.5, while TG≥100.5 mg/dl was 75.3% 
(73) amongst the overweight/obese women. The difference 
was not significant. Moreover, hormonal results indicate that 
overweight/obese PCOS patients had lower SHBG and 
elevated prolactin concentration (p< 0.05, p<0.001).  
Glucose findings: Table 4 demonstrated that the prevalence 
of IR (HOMA >3.15) revealed 47.1 %( 53) and HOMA-IR≤ 
3.15 was 49% (57) irrespective of whether they were normal, 
overweight/obese that displays significant difference 
(P<0.00) (table 4).  
Fig 1 revealed higher mean of Homa (IR) data for  
 
 
overweight/obese vs. normal control PCOS women 72.5% 
(76) of our participants had quantitative IS check index 
(QUICKI)<0.34 and 27.5%(32) had QUICKI ≥0.34 without 
considering BMI classification. More than 80% of 
overweight/obese PCOS patients showed low IS (QUICKI 
<0.34) and over 90% of these groups of patients revealed 
high IR (HOMA>3.15) (table 2).  
Additionally, the elevated mean of QUICKI in 
overweight/obese vs. normal weight PCOS women was 
displayed in fig 2. To assess fasting blood sugar (FBS), we 
applied optimal cutoff >100.9 mg/dl (5.7 mmol/L or 5.6 
mmol/L or more) for fasting plasma glucose according to 
Gagnon (32). FBS in 89.2% (95) was less than 100.9 mg/dl 
and 10.8% (14) was over apart from the BMI classification 
(table 4).  
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Figure 1: Mean Homa(IR) data for normal control, 
overweight/obese PCOs women. Groups were 
significantly different from each other (p<0.001), 
(p<0.001), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Comparison of QUICKI in BMI- classified 
(normal and overweight/obese) PCOs women. Groups 
were significantly different from each other 
 (p<0.001), (p<0.001), respectively 
 
Comparison of the diagnosis with high accuracy of two 
cutoff fasting insulin values (<7 and ≥13 µg/dl) is 
represented by Lunger (30). In our study, 15.7% (18) of 
women had fasting insulin less than 7 µg/dl and 56.9 % (61) 
of women ≥13 µg/dl irrespective of BMI classification. Over 
85% (54) of our overweight/obese PCOS patients revealed 
fasting insulin≥13 versus 10.3 % (7) in the normal PCOs 
control.  
Nonetheless, the women with insulin level<7 µg/dl are 
similar within two groups. 
Table 4. Insulin parameters in normal and 
overweight/obese PCOs women 
 
  Normal Overweight/Obese Pvalue 
Fasting glucose 
(mg/dl) 
<100.9 27.5(26) 72.5(68) 0.5 
≥100.9 18.2(4) 81.8(12) 
Fasting Insulin  <7   50%(8) 50%(8) <0.001 
(µU/ml) ≥ 7 and 
<13 
46.4%(14) 53.6%(17) 
 
 ≥13 10.3%(7) 89.7%(54)  
HOMA(IR) 
 
≤3.15 38%(22) 62%(35) <0.001 
>3.15 8.3%(5) 91.7%(48) 
QUICKI   ≥0.34 50%(16) 50%(16) <0.001 
<0.34 17.6%(13) 82.4%(62) 
The values is significant at P≤0.05, rates were compared with chi- 
square test. 
Overweight and obese (body mass index [BMI] ≥25 kg/m2 
PCOs; Polycystic ovarian syndrome 
HOMA-IR: Insulin resistance calculated using HOMA model  
QUICKI: Insulin sensitivity calculated using QUICKI model 
 
Discussion 
In the current study, we found that over 90% of the 
overweight/obese PCOs patients showed high IR and over 
80% of them showed decreased IS. Moreover, 85% of the 
overweight/obese PCOs participants demonstrated elevated 
fasting insulin concentration. 
Morciano’s classified 72% of Italian overweight/ obese 
women as insulin resistant compared with 26.3% of the lean 
counterpart and the difference was significant (27). 
Morciano’ findings are in agreement with those obtained by 
us; however, the discrepancy in the rates could be attributed 
to the method of IR calculation and ethnic variation. He 
evaluated IR through hyperinsulinemic- euglycemic clamp. 
Besides, our findings are in accordance with the study by 
Stepo et al. in Australia indicating that 95% of overweight/ 
obese PCOs and 75% of lean PCOS women are in the risk of 
IR (17). He also evaluated IR through hyperinsulinemic- 
euglycemic clamp. Yet, Stepo’ finding need doubtless be 
scrutinized whereas he did not mention his samples were 
taken from similar races or not. Wijeyaratne et al. found IS 
to be lower in women of the Middle East (22). Taking into 
account racial homogeneity, we applied IR specific cutoff 
value ≥ 3.15 for PCOs women in which Alebic et al. 
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recommended in their paper (13). Behboudi-Gandevani et al. 
in an earlier review article revealed that the mean of HOMA 
IR in Iranian obese PCOs group was 4.38 which are more 
than their non- obese counterparts and the difference was 
significant. They found no evidence of any effects of obesity 
on IR sensitivity (33). Another study in Iran demonstrated 
that 36% of overweight/ obese PCOs patients had insulin 
resistance. Their excess rate may be somewhat limited by 
excess HOMA (IR) (≥3.8) that they considered as insulin-
resistant criteria (34). 
Irrespective of age and body mass index, race and 
lifestyle (diet) may have a pivotal role in the overall 
prevalence of IR. Glintborg et al. in their study demonstrated 
that the risk of diabetes was comparable between the Middle 
East and Caucasian populations in Denmark, while the 
frequency of fasting insulin was enhanced in the Middle East 
PCOS women (35). With respect to the adjacent countries 
which may have similar races to Iran, Jamil et al. reported IR 
was 42.6% (cutoff value of HOMA-IR ≥3.8 for PCOS 
women) within Iraq’s PCOs women and Tabassum et al. in 
Pakistan that his obtained prevalence of IR was 34.80% (36-
37). The data in the first study approximately accorded with 
what we found in our study. Possible explanations for the 
difference in the recent mentioned study by Tabassum can be 
attributed to the type of applied measurement tools of IR that 
was calculated by means of insulin ratio. 
Another important finding was that 85% of overweight/ 
obese PCOs patients had elevated fasting insulin 
concentration with highly statistically significance compared 
with normal PCOs controls. Schachter addressed IR 
identified in 53.5% (83/155) of PCOs patients (38). He 
calculated fasting insulin >19.1 mIU/l. This low result is 
likely to be related to the rather range of fasting insulin level 
that they considered as criterion of insulin level (29). 
Contrary to expectations, this study did not find a 
significant difference between fasting glucose concentration 
in normal weight as opposed to overweight/obese; however, 
this value was enhanced in the women with adiposity. This 
result further supports the idea of Gagnon that claimed 
screening for abnormal glucose tolerance when the results of 
a fasting plasma glucose test are 5.6 mmol/L or more are not 
reasonable for women with polycystic ovary syndrome (32). 
Also, Palmert et al.’s study seems to be consistent with our 
study and identified that fasting glucose level is a suboptimal 
criterion at least for impaired diabetes diagnosis (39). On the 
question of other metabolic profile, this study detects the 
evidence that women with greater BMI have less SHBG. 
These findings support previous research into this brain area 
that hyperinsulinemia exacerbate androgen production as 
well as declining sex hormone-binding globulin (40). We 
also observed excess triglyceride and LDL cholesterol in 
overweight/obese women versus normal weight ones. This 
result is in consistence with Layegh and et al. (41). Park et 
al. in their study investigated that TG≥100.5 in obese group 
is a best marker for predicting IR (HOMA-IR≥2.5) in 
Korean obese and non-obese PCOs women. In our study, 
more than 75% of the overweight/obese women had 
TG≥100.5 and predicted IR (HOMA-IR>3.15). The result 
needs to be considered cautiously for the greater HOMA-IR 
that we applied for calculation IR according to Park (31). A 
limitation consist of not using glucose tolerance test (GTT) 
and comparing that with other respective tests to entirely 
characterize the IR owing to having not enough budget. 
Further research is required to determine the racial 
variability in intrinsic IR and BMI-related IR. 
In conclusion majority of the overweight/obese PCOS 
patients showed higher insulin resistance, lower insulin 
sensitivity and elevated fasting insulin concentration vs. their 
normal weight counterparts. PCOs women are more prone to 
adiposity and excess body mass index was associated with 
IR. Consequently, IR disorders androgen profile and 
threatens metabolic and reproductive health across life span, 
accordingly, health strategy needs to be screened for the 
diagnosis of IR in all young PCOs overweight/obese women.  
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